Canaccord Adams Raises Price Target On Labopharm (DDSS) After Oleptro Approval, Partnership Is Next
Tweet Send to a Friend
Canaccord Adams raised their price target on Labopharm Inc. (Nasdaq: DDSS) from C$2.80 to $C$3.15 after the company gained FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
